Welcome

Sign out Have a question? We're here to help

Copyright © 2020 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Novabay Pharmaceuticals (NBY)

$0.63 0.01 (1.26%)

20:00 EST NBY Stock Quote Delayed 15 Minutes

Volume:

Previous Close $0.63

Market Cap 10.73M

PE Ratio -1.74

EPS -0.36

Volume (Avg. Vol.) 223,900

Day's Range 0.61 - 0.64

52-Week Range 0.23 - 4.04

Dividend & Yield N/A (N/A)

NBY Stock Predictions, Articles, and Novabay Pharmaceuticals News

From the Web

NovaBay launches NovaWipes eyelid wipes on Amazon.com; shares up 22% premarket

From Seeking Alpha Dec 2, 2019

NovaBay Pharmaceuticals (NYSEMKT:NBY) has launched NovaWipes, a dry, soft, hypoallergenic and absorbable wipe for use in applying Avenova, on Amazon.com. NovaWipes are available in a 30-count package

77 Biggest Movers From Yesterday

From Benzinga Nov 20, 2019

Gainers Myovant Sciences Ltd (NYSE: MYOV) shares jumped 113.2% to close at $12.92 on Tuesday after the company announced that its Phase 3 HERO study of once-daily, oral relugolix...

51 Stocks Moving In Tuesday's Mid-Day Session

From Benzinga Nov 19, 2019

Gainers Myovant Sciences Ltd (NYSE: MYOV) shares surged 156% to $15.51 after the company announced that its Phase 3 HERO study of once-daily, oral relugolix met its primary...

72 Biggest Movers From Yesterday

From Benzinga Nov 19, 2019

Gainers Karuna Therapeutics, Inc. (NASDAQ: KRTX) shares climbed 443% to close at $96.00 on Monday after the company announced its phase 2 trial of KarXT in patients with...

Mid-Afternoon Market Update: Qudian Falls Following Downbeat Q3 Earnings; NovaBay Pharmaceuticals Shares Jump

From Benzinga Nov 18, 2019

Toward the end of trading Monday, the Dow traded up 0.07% to 28024.60 while the NASDAQ rose 0.07% to 8,546.86. The S&P also rose, gaining 0.04% to 3,121.69. Leading and...

44 Stocks Moving In Monday's Mid-Day Session

From Benzinga Nov 18, 2019

Gainers Karuna Therapeutics, Inc. (NASDAQ: KRTX) shares surged 233.7% to $58.99 after the company announced its phase 2 trial of KarXT in patients with schizophrenia met its...